Access Biotechnology
VC Fund
New York, United States
Access Biotechnology is a VC fund in New York focused on Biotechnology and Health Care. Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – fromdiscovery-stage technology platforms to late-stage clinical programs.The company is based in New York.
- Total investments:
- 48
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Access Biotechnology invests in
Stages Access Biotechnology invests in
Countries Access Biotechnology invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Biotechnology 26 (54%)
- Health Care 17 (35%)
- Therapeutics 15 (31%)
- Medical 10 (21%)
- Pharmaceutical 10 (21%)
Stage
- Series B 13 (27%)
- Series A 12 (25%)
- Post-IPO Equity 9 (19%)
- Series C 2 (4%)
- Funding Round 2 (4%)
Country
- United States 26 (54%)
- Denmark 1 (2%)
- Australia 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christine Borowski
Senior Associate
|
Senior Associate | Total investments: 3 | Find email | |
Dan Becker
Principal
|
Principal | Total investments: 15 | Find email | |
Jeffrey Ives
Advisor
|
Advisor | Total investments: 0 | Find email | |
Liam Ratcliffe
Head of Biotechnology
|
Head of Biotechnology | Total investments: 17 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OnKure Therapeutics
|
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M / Post-IPO Equity / Mar 27, 2026 | |
Recludix Pharma
|
Recludix pharma is a developing platform to discover potent and selective inhibitors of challenging protein targets. The platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. | Jan 12, 2026 | |
Hemab
|
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $157M / Series C / Oct 27, 2025 | |
Draig Therapeutics
|
Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $140M / Series A / Jun 18, 2025 | |
Surrozen
|
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. | $175M / Post-IPO Equity / Mar 24, 2025 | |
Latigo Biotherapeutics
|
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability. | $150M / Series B / Mar 17, 2025 | |
Oruka Therapeutics
|
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases. | $275M / Post-IPO Equity / Sep 03, 2024 | |
Halda Therapeutics
|
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $126M / Series B / Aug 12, 2024 | |
Day One Biopharmaceuticals
|
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of peopleof all ages living with cancer starting from the biology of childhood cancer.Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA. | $175M / Post-IPO Equity / Jul 30, 2024 | |
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $60.3M / Series B / Jul 19, 2024 | |
| See all 48 investments → | |||
Co-Investors
RA Capital Management
22 deals together
Atlas Venture
15 deals together
OrbiMed
13 deals together
Deep Track Capital
9 deals together
Novo Holdings
9 deals together
Canaan Partners
8 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Access Biotechnology invest in?
Access Biotechnology invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 48 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Access Biotechnology?
Public channels for Access Biotechnology include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Access Biotechnology?
The team at Access Biotechnology includes Christine Borowski (Senior Associate), Dan Becker (Principal) and Jeffrey Ives (Advisor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
